NEWS CENTER

TCT 2022丨RainMed caIMR Presented at the Transcatheter Cardiovascular Therapeutics Conference, Providing a New Solution for Global Coronary Microcirculation Function Assessment

  • Categories:News Center
  • Author:
  • Origin:
  • Time of issue:2022-09-30 14:18
  • Views:

(Summary description)RainMed Medical, an innovative medical device enterprise from China, was invited to deliver a speech at TCT to announce its latest clinical trial data because of the original breakthrough technology of caIMR in coronary microcirculation function assessment, which showed the world China's local innovation strength.

TCT 2022丨RainMed caIMR Presented at the Transcatheter Cardiovascular Therapeutics Conference, Providing a New Solution for Global Coronary Microcirculation Function Assessment

(Summary description)RainMed Medical, an innovative medical device enterprise from China, was invited to deliver a speech at TCT to announce its latest clinical trial data because of the original breakthrough technology of caIMR in coronary microcirculation function assessment, which showed the world China's local innovation strength.

  • Categories:News Center
  • Author:
  • Origin:
  • Time of issue:2022-09-30 14:18
  • Views:
Information

On September 16th, Boston time, the 2022 American Transcatheter Cardiovascular Therapeutics (TCT 2022) conference was officially held online and offline. Global cardiovascular giants such as Medtronic and Edward Life Sciences all released their latest academic progress. RainMed Medical, an innovative medical device enterprise from China, was invited to deliver a speech at the conference to announce its latest clinical trial data because of the original breakthrough technology of caIMR in coronary microcirculation function assessment, which showed the world China's local innovation strength.

 

Debuting as a small gathering of 150 in 1988, the Transcatheter Cardiovascular Therapeutics (TCT) conference now attracts more than 10,000 attendees from more than 100 countries. It has become the Cardiovascular Research Foundation's (CRF) annual scientific symposium and the world's foremost educational forum specializing in interventional cardiovascular medicine. Every year, TCT features major medical research breakthroughs and gathers leading researchers and clinicians from around the world to present and discuss the latest evidence-based research.

 

 

The TCT conference has always been a bellwether in the field of cardiology, and the new technologies and products unveiled at the conference have all congealed the wisdom of countless researchers and clinicians in the field of cardiology. With the help of the conference, more accurate medical devices and advanced diagnostic technology will gradually go out to the world and create a new era of cardiovascular diagnosis.

 

At the conference, the representative of RainMed Medical introduced the background of coronary microvascular disease diagnosis and treatment. Coronary microvascular disease (CMVD) is a common condition and is the main cause of myocardial ischemia and has a poor prognosis. 40% of patients with coronary disease still suffer from recurrent angina after PCI, partly because of microcirculatory dysfunction. The diagnosis of CMVD requires four elements: ischemic symptoms, objective evidence of ischemia, epicardial vascular conditions, and microvascular physiological function. And IMR can be used as an important index to evaluate microvascular function. Compared with CFR, IMR can specifically reflect coronary microcirculation function, and its repeatability is higher than CFR. Therefore, the use of IMR to assess coronary microvascular dysfunction has been recommended by many relevant guidelines and consensus.

 

 

Despite these advances, there are currently no products on the market that can measure IMR without intervention. Traditional guidewire-based IMR detection technology requires pressure guide wire, hyperemic agents, and repeated injections of SPSS. Since the operation is complex and risky, it is mostly used in scientific research rather than daily application.

 

In response to this problem, RainMed Medical has been working hard for nearly ten years to launch the caIMR system, the index of coronary microcirculatory resistance system, which brings a new treatment option for the evaluation of microcirculation function. RainMeds caIMR system directly calculates IMR based on angiograms. Compared with guidewire-based IMR technology, there is no need of pressure guidewire, hyperemic agents, repeated injection of SPSS, which has outstanding advantages of safety, convenience and efficiency. caIMR can measure IMR value in real time during the operation without changing the physician's surgical habits, and the diagnosis time can be shortened from 40-60 minutes to an average of 5 minutes. It can significantly reduce the risk during the operation caused by interventional measurement, assist the physicians to develop a better diagnosis and treatment plan, reduce the waste of surgical resources, and improve the efficiency of surgery.

 

caIMR has brought a new option for microcirculation treatment. Its simple operation and accurate, safe and efficient evaluation of coronary microcirculation function have made Chinese research attracted the attention of the world. RainMed also presented key data from the caIMR randomized controlled trial at the TCT conference. Flash III is a prospective, multicenter, blinded design registered clinical experiment to evaluate the efficacy and safety of caIMR. Academician Junbo Ge and Professor Yong Huo served as co-PI. In the Flash III clinical trial, 116 subjects accepted both caIMR test and guide wire-derived IMR test. Using caIMR25, IMR25 as the cut-off value to determine coronary microcirculation dysfunction, result showed that the accuracy of online and offline measurement was as high as 93.81% and 94.69% respectively, showing important academic value and clinical potential. In the future, RainMed caIMR will have huge application prospects, or will become the world's first innovative IMR product approved for marketization to meet the blue ocean market of more than 10 billion yuan.

 

As one of the few domestic enterprises with global innovation capability, RainMed Medical did not follow the traditional interventional therapy and its development direction, but deeply explored clinical needs and developed safer and more efficient coronary microcirculation diagnostic and evaluation products from zero-to-one. caIMR, as an innovative breakthrough product developed in China, demonstrates the rich clinical resources, solid and rigorous academic research and commercialization capabilities of RainMed Medical in the past ten years.

 

With the end of the TCT conference, the innovation strength from China has become the leading role of global attention, bringing breakthrough achievements, which means that local innovation is no longer just a follower, and Chinese innovation can also be recognized globally, which is of great significance for China's medical device industry.

 

In the future, RainMed Medical will continue to uphold the purpose of "Targeted medical services for people's health", innovatively launch vascular interventional surgery robot to gradually form an "unmanned operating room" in order to promote the development of cardiovascular health in China.

CONTACT US

0512-62622215

Address: Building 31, Northeast District, Nano City, No. 99 Jinji Lake Avenue, Suzhou industrial park

这是描述信息

WeChat public account

这是描述信息

Recruitment QR Code

We use cookies to improve our site and your shopping experience. By continuing to browse our site you accept our cookie policy. Find out more
close

Page Copyright© 2021- Suzhou Rainmed Medical Technology Co., Ltd.  苏公网安备32059002003601号  (苏)-非经营性-2021-0149